Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2006

View Archived Issues

Pharmexa updates pipeline progress

BMS-275291 well tolerated in hormone-refractory prostate cancer

Continual paroxetine therapy reduces depression recurrence in the elderly

Renal effects of ISIS-113715 investigated in monkeys

ES-285 adminstration feasible when given once every 3 weeks in cancer patients

Pooled studies show efficacy of duloxetine in diabetic peripheral neuropathic pain

AC-100 enhances bone formation in tooth extraction model

Albumin can safely reduce interferon alpha clearance in hepatitis C patients

BMS-587101: new LFA-1 antagonist in phase II study for psoriasis

New TRPV1 antagonists for pain profiled at ACS meeting

Ono and Medarex collaborate on development of anti-SDF-1 antibodies

Medarex grants full European commercialization rights for DTS-201 to Diatos

SGX and Novartis team up on Bcr-Abl inhibitors for drug-resistant CML

Phase I study begins for PulmoLAR

Dynavax to acquire Rhein Biotech GmbH

Phase Ib study under way for neurodegenerative compound AL-208

Positive findings for phase IIb study of Pollinex Quattro Ragweed vaccine

PanGenetics closes series B financing

BioBalance to begin clinic trials of Probactrix for pouchitis

Phase I trial cleared to study dendritic cell strategy in treatment of diabetes

Seretide reduces mortality in COPD patients

New adenosine A2A antagonist from Schering-Plough in phase II for Parkinson's

New treatment options reported for thrombotic disorders

Novel compounds with potential for the treatment of neurological disorders disclosed

Recent patents claim agents for gastrointestinal disorders

Axcan submits NDA amendment for Helizide

Galvus NDA accepted for review

Swiss approval for Nexavar in advanced kidney cancer

Synthesis of novel himbacine-based PAR-1 antagonists reported

Pfizer presents preclinical and clinical data on novel TAFI inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...